David J. Pinsky

David J. Pinsky

Auto-generated profile, based on publicly available information

David J. Pinsky

Division of Cardiovascular Medicine Samuel and Jean Frankel Cardiovascular Center University of Michigan Ann Arbor MI 48109 USA

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 March 2020 in Scientific Reports
Verified
Journal Article
Open access
PDF file
CACarmel Ashur
Carmel Ashur
ENElizabeth Norton
Elizabeth Norton
LFLinda Farhat
Linda Farhat
ACAnna Conlon
Anna Conlon
CWCristen Willer
Cristen Willer
MBMarion A. Hofmann Bowman
Marion A. Hofmann Bowman
Triggering events for acute aortic dissections are incompletely understood. We sought to investigate whether there is an association between admission for acute type A aortic dissection (ATAAD) to the University of Michigan Medical Center and the reported annual influenza activity by the Michigan Department of Health and Human Services. From 1996–2019 we had 758 patients admitted for ATAAD with 3.1 admissions per month during November-March and 2.5 admissions per month during April-October (p = 0.01). Influenza reporting data by the Michigan Department of Health and Human Services became available in 2009. ATAAD admissions for the period 2009–2019 (n = 455) were 4.8 cases/month during peak influenza months compared to 3.5 cases/month during non-peak influenza months (p = 0.001). ATAAD patients admitted during influenza season had increased in-hospital mortality (11.0% vs. 5.8%, p = 0.024) and increased 30-day mortality (9.7 vs. 5.4%, p = 0.048). The results point to higher admission rates for ATAAD during months with above average influenza rates. Future studies need to investigate whether influenza virus infection affects susceptibility for aortic dissection, and whether this risk can be attenuated with the annual influenza vaccine in this patient population.

6 May 2021 in PLOS Computational Biology
Verified
Journal Article
Open access
PDF file
AMAndrew D. Marquis
Andrew D. Marquis
FJFilip Jezek
Filip Jezek
DPDavid J. Pinsky
David J. Pinsky
DBDaniel A. Beard
Daniel A. Beard
The relationship between regional variabilities in airflow (ventilation) and blood flow (perfusion) is a critical determinant of gas exchange efficiency in the lungs. Hypoxic pulmonary vasoconstriction is understood to be the primary active regulator of ventilation-perfusion matching, where upstream arterioles constrict to direct blood flow away from areas that have low oxygen supply. However, it is not understood how the integrated action of hypoxic pulmonary vasoconstriction affects oxygen transport at the system level. In this study we develop, and make functional predictions with a multi-scale multi-physics model of ventilation-perfusion matching governed by the mechanism of hypoxic pulmonary vasoconstriction. Our model consists of (a) morphometrically realistic 2D pulmonary vascular networks to the level of large arterioles and venules; (b) a tileable lumped-parameter model of vascular fluid and wall mechanics that accounts for the influence of alveolar pressure; (c) oxygen transport accounting for oxygen bound to hemoglobin and dissolved in plasma; and (d) a novel empirical model of hypoxic pulmonary vasoconstriction. Our model simulations predict that under the artificial test condition of a uniform ventilation distribution (1) hypoxic pulmonary vasoconstriction matches perfusion to ventilation; (2) hypoxic pulmonary vasoconstriction homogenizes regional alveolar-capillary oxygen flux; and (3) hypoxic pulmonary vasoconstriction increases whole-lobe oxygen uptake by improving ventilation-perfusion matching.

19 June 2024 in Advanced Healthcare Materials
Verified
Journal Article
Open access
EBEmma R. Brannon
Emma R. Brannon
LPLogan D. Piegols
Logan D. Piegols
GCGillian Cady
Gillian Cady
DKDaniel Kupor
Daniel Kupor
XCXueqi Chu
Xueqi Chu
OAOmolola Eniola Adefeso
Omolola Eniola Adefeso
Neutrophils can contribute to inflammatory disease propagation via innate mechanisms intended for inflammation resolution. For example, neutrophil extracellular traps (NETs) are necessary for trapping pathogens but can contribute to clot formation and blood flow restriction, that is, ischemia. Currently, no therapeutics in the clinic directly target NETs despite the known involvement of NETs contributing to mortality and increased disease severity. Vascular‐deployed particle‐based therapeutics are a novel and robust alternative to traditional small‐molecule drugs by enhancing drug delivery to cells of interest. This work designs a high‐throughput assay to investigate the immunomodulatory behavior and functionality of salicylic acid‐based polymer‐based particle therapeutics against NETosis in human neutrophils. Briefly, this work finds that polymeric composition plays a role, and particle size can also influence rates of NETosis. Salicylate‐based polymeric (Poly‐SA) particles are found to functionally inhibit NETosis depending on the particle size and concentration exposed to neutrophils. This work demonstrates the high throughput method can help fast‐track particle‐based therapeutic optimization and design, more efficiently preparing this innovative therapeutics for the clinic.

19 October 2022 in Cardiovascular Drugs and Therapy
Verified
Journal Article
Closed access
PDF file
OGOlga G. Grushko
Olga G. Grushko
SCSteven X. Cho
Steven X. Cho
ATAshley M. Tate
Ashley M. Tate
RRRobert S. Rosenson
Robert S. Rosenson
DPDavid J. Pinsky
David J. Pinsky
SGSascha N. Goonewardena
Sascha N. Goonewardena

1 May 1995 in American Journal of Physiology-Heart and Circulatory Physiology
Verified
Journal Article
Closed access
PDF file
CLC. A. Lawson
C. A. Lawson
ASA. J. Smerling
A. J. Smerling
YNY. Naka
Y. Naka
DBD. Burkhoff
D. Burkhoff
MDM. L. Dickstein
M. L. Dickstein
DPD. J. Pinsky
D. J. Pinsky
Selective reduction of pulmonary vascular resistance (PVR) remains a therapeutic goal for the treatment of pulmonary hypertension, but current therapeutic options remain limited. Although the gas nitric oxide (NO) selectively dilates the pulmonary vascular bed, it requires special equipment for administration, has a short biologic half-life, and is potentially toxic. We hypothesized that stimulation of the NO pathway at the level of its second messenger, guanosine 3',5'-cyclic monophosphate (cGMP), by targeted pulmonary delivery of a membrane-permeable nonhydrolyzable cGMP analogue would cause selective pulmonary vasodilation. Pulmonary hypertension was induced in 21 pigs by the intravenous infusion of a thromboxane A2 analogue (9,11-dideoxy-9 alpha,11 alpha-epoxymethanoprostaglandin F2 alpha). Inhaled 8-bromoguanosine 3',5'-cyclic monophosphate (8-BrcGMP) lowered PVR in a time- and dose-dependent manner, with maximal effect achieved after 20 min. Compared with physiological saline control, 8-BrcGMP inhalation (3.0 micrograms/kg) lowered PVR by 25 +/- 3% (P < 0.01), whereas there was no significant decline in systemic vascular resistance (4 +/- 6%); mean pulmonary arterial pressure declined 13 +/- 3% (P < 0.01), whereas there was little change in mean arterial pressure; cardiac output increased 10 +/- 4% (P < 0.05). PVR did not decrease after inhalation of noncyclic 8-bromoguanosine 5'-monophosphate, indicating that stimulation of the NO-cGMP pathway beyond the level of NO results in pulmonary vasodilation independent of stimulation of purinergic receptors.(ABSTRACT TRUNCATED AT 250 WORDS)